| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| CTLA-4 Antigen | 90 | 2024 | 678 | 10.170 |
Why?
|
| Immunotherapy | 69 | 2024 | 3557 | 5.330 |
Why?
|
| T-Lymphocytes | 83 | 2021 | 3949 | 4.560 |
Why?
|
| Lymphocyte Activation | 57 | 2021 | 1723 | 4.390 |
Why?
|
| Antigens, CD | 51 | 2011 | 1418 | 3.920 |
Why?
|
| Antigens, Differentiation | 28 | 2011 | 247 | 3.700 |
Why?
|
| CD4-Positive T-Lymphocytes | 32 | 2024 | 1051 | 3.610 |
Why?
|
| CD8-Positive T-Lymphocytes | 47 | 2024 | 1655 | 3.520 |
Why?
|
| B7-1 Antigen | 19 | 2011 | 84 | 3.390 |
Why?
|
| Antibodies, Monoclonal | 71 | 2022 | 4481 | 3.240 |
Why?
|
| T-Lymphocytes, Regulatory | 32 | 2024 | 714 | 3.200 |
Why?
|
| T-Lymphocyte Subsets | 24 | 2021 | 593 | 3.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 27 | 2024 | 1097 | 3.090 |
Why?
|
| CD28 Antigens | 25 | 2016 | 202 | 2.910 |
Why?
|
| Melanoma, Experimental | 17 | 2021 | 382 | 2.910 |
Why?
|
| Neoplasms | 59 | 2024 | 15927 | 2.770 |
Why?
|
| Receptors, Antigen, T-Cell | 44 | 2021 | 1137 | 2.730 |
Why?
|
| Ipilimumab | 41 | 2024 | 764 | 2.590 |
Why?
|
| Receptors, Immunologic | 14 | 2024 | 313 | 2.210 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 11 | 2024 | 78 | 1.960 |
Why?
|
| Melanoma | 41 | 2023 | 5595 | 1.940 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 25 | 2021 | 1032 | 1.860 |
Why?
|
| Antineoplastic Agents, Immunological | 18 | 2022 | 1335 | 1.670 |
Why?
|
| Cancer Vaccines | 21 | 2024 | 754 | 1.570 |
Why?
|
| Animals | 197 | 2024 | 61956 | 1.550 |
Why?
|
| Mice | 152 | 2024 | 35600 | 1.540 |
Why?
|
| T-Lymphocytes, Cytotoxic | 11 | 2023 | 1020 | 1.430 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 16 | 2010 | 170 | 1.420 |
Why?
|
| Mice, Inbred C57BL | 62 | 2024 | 7100 | 1.400 |
Why?
|
| Antigens, Neoplasm | 25 | 2024 | 1580 | 1.380 |
Why?
|
| Prostatic Neoplasms | 24 | 2020 | 5866 | 1.360 |
Why?
|
| Membrane Glycoproteins | 11 | 2024 | 1094 | 1.220 |
Why?
|
| V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 6 | 2024 | 33 | 1.190 |
Why?
|
| Thymus Gland | 13 | 2019 | 311 | 1.140 |
Why?
|
| Immunoconjugates | 9 | 2021 | 314 | 1.070 |
Why?
|
| Autoimmunity | 7 | 2017 | 267 | 1.060 |
Why?
|
| B7 Antigens | 6 | 2019 | 84 | 1.050 |
Why?
|
| Allergy and Immunology | 3 | 2012 | 30 | 1.020 |
Why?
|
| Mice, Knockout | 27 | 2024 | 5728 | 0.960 |
Why?
|
| Immune Tolerance | 8 | 2024 | 427 | 0.920 |
Why?
|
| Forkhead Transcription Factors | 10 | 2019 | 763 | 0.900 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 3 | 2015 | 76 | 0.900 |
Why?
|
| Immunologic Memory | 5 | 2020 | 380 | 0.900 |
Why?
|
| Signal Transduction | 29 | 2024 | 12103 | 0.880 |
Why?
|
| Mice, Transgenic | 31 | 2024 | 4223 | 0.870 |
Why?
|
| Listeriosis | 2 | 2015 | 43 | 0.860 |
Why?
|
| Oncolytic Virotherapy | 2 | 2017 | 239 | 0.850 |
Why?
|
| Humans | 203 | 2024 | 270740 | 0.840 |
Why?
|
| Colorectal Neoplasms | 11 | 2023 | 3707 | 0.840 |
Why?
|
| Epitopes, T-Lymphocyte | 6 | 2012 | 228 | 0.790 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 24 | 2024 | 16689 | 0.780 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 16 | 1995 | 172 | 0.770 |
Why?
|
| Early Detection of Cancer | 7 | 2023 | 1340 | 0.760 |
Why?
|
| Occult Blood | 5 | 2023 | 63 | 0.750 |
Why?
|
| Lymphoma | 12 | 2019 | 1519 | 0.740 |
Why?
|
| Drug Resistance, Neoplasm | 11 | 2021 | 5408 | 0.730 |
Why?
|
| Neoplasms, Experimental | 8 | 2018 | 784 | 0.730 |
Why?
|
| Newcastle disease virus | 2 | 2017 | 7 | 0.690 |
Why?
|
| Skin Neoplasms | 12 | 2021 | 4895 | 0.680 |
Why?
|
| Antibodies, Neoplasm | 6 | 2009 | 273 | 0.680 |
Why?
|
| Immunologic Surveillance | 4 | 2016 | 59 | 0.670 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 5 | 2011 | 96 | 0.670 |
Why?
|
| Lymphopoiesis | 1 | 2019 | 17 | 0.660 |
Why?
|
| Tumor Microenvironment | 20 | 2024 | 3035 | 0.650 |
Why?
|
| Gene Expression Regulation | 12 | 2017 | 4130 | 0.640 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 3 | 2015 | 67 | 0.640 |
Why?
|
| Cell Line, Tumor | 30 | 2024 | 14849 | 0.630 |
Why?
|
| Cell Differentiation | 20 | 2015 | 4116 | 0.630 |
Why?
|
| Interferon-gamma | 11 | 2016 | 1179 | 0.630 |
Why?
|
| Adenocarcinoma | 13 | 2019 | 7914 | 0.600 |
Why?
|
| Oncolytic Viruses | 2 | 2017 | 169 | 0.600 |
Why?
|
| Lymphocyte Count | 13 | 2020 | 485 | 0.600 |
Why?
|
| Tissue Extracts | 2 | 2021 | 50 | 0.570 |
Why?
|
| Flow Cytometry | 24 | 2019 | 3045 | 0.570 |
Why?
|
| Ligands | 11 | 2018 | 1012 | 0.570 |
Why?
|
| Antibodies, Monoclonal, Humanized | 10 | 2021 | 3409 | 0.560 |
Why?
|
| Histocompatibility Antigens | 9 | 2012 | 79 | 0.550 |
Why?
|
| Myocarditis | 3 | 2024 | 181 | 0.550 |
Why?
|
| Abatacept | 9 | 2024 | 40 | 0.540 |
Why?
|
| B7-H1 Antigen | 10 | 2023 | 1089 | 0.530 |
Why?
|
| Mice, Inbred BALB C | 27 | 2019 | 2454 | 0.510 |
Why?
|
| B-Lymphocytes | 10 | 2023 | 1424 | 0.510 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 7 | 2013 | 425 | 0.500 |
Why?
|
| Immune System | 6 | 2018 | 275 | 0.500 |
Why?
|
| Colitis | 5 | 2022 | 341 | 0.500 |
Why?
|
| Autoantigens | 5 | 2022 | 248 | 0.490 |
Why?
|
| Listeria monocytogenes | 2 | 2015 | 61 | 0.490 |
Why?
|
| Peptides | 12 | 2015 | 1504 | 0.480 |
Why?
|
| Granzymes | 4 | 2024 | 94 | 0.480 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2020 | 1840 | 0.480 |
Why?
|
| Awards and Prizes | 1 | 2015 | 86 | 0.470 |
Why?
|
| Antigens, Surface | 16 | 2005 | 306 | 0.460 |
Why?
|
| Histocompatibility Antigens Class II | 7 | 2024 | 189 | 0.460 |
Why?
|
| Hemoglobin Subunits | 1 | 2013 | 1 | 0.460 |
Why?
|
| Monitoring, Immunologic | 2 | 2011 | 47 | 0.460 |
Why?
|
| Feces | 4 | 2023 | 861 | 0.460 |
Why?
|
| Antineoplastic Agents | 15 | 2021 | 14617 | 0.450 |
Why?
|
| Male | 85 | 2024 | 128315 | 0.450 |
Why?
|
| Health Care Reform | 1 | 2014 | 64 | 0.450 |
Why?
|
| Receptors, OX40 | 3 | 2019 | 51 | 0.440 |
Why?
|
| Immunization, Passive | 2 | 2011 | 188 | 0.440 |
Why?
|
| Antigen-Presenting Cells | 8 | 2013 | 286 | 0.440 |
Why?
|
| Dendritic Cells | 13 | 2024 | 1110 | 0.440 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 3 | 2024 | 466 | 0.430 |
Why?
|
| Combined Modality Therapy | 18 | 2022 | 9039 | 0.430 |
Why?
|
| Th2 Cells | 2 | 2005 | 252 | 0.430 |
Why?
|
| Inflammatory Bowel Diseases | 4 | 2012 | 346 | 0.430 |
Why?
|
| T-Box Domain Proteins | 2 | 2013 | 154 | 0.420 |
Why?
|
| Hepatitis, Autoimmune | 2 | 2012 | 53 | 0.420 |
Why?
|
| History, 20th Century | 6 | 2015 | 544 | 0.420 |
Why?
|
| Antibodies, Blocking | 4 | 2013 | 95 | 0.410 |
Why?
|
| Disease Models, Animal | 19 | 2020 | 7381 | 0.410 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 8 | 2016 | 185 | 0.410 |
Why?
|
| Neoplasm Metastasis | 11 | 2021 | 5315 | 0.400 |
Why?
|
| Societies, Scientific | 1 | 2012 | 68 | 0.400 |
Why?
|
| Growth Inhibitors | 1 | 2012 | 164 | 0.400 |
Why?
|
| Nobel Prize | 1 | 2011 | 9 | 0.400 |
Why?
|
| Macrophages | 8 | 2022 | 1350 | 0.400 |
Why?
|
| Adoptive Transfer | 5 | 2014 | 431 | 0.400 |
Why?
|
| Killer Cells, Natural | 6 | 2015 | 965 | 0.400 |
Why?
|
| Cell Cycle Checkpoints | 4 | 2020 | 271 | 0.400 |
Why?
|
| Hemoglobins | 1 | 2014 | 482 | 0.400 |
Why?
|
| Ikaros Transcription Factor | 1 | 2011 | 53 | 0.390 |
Why?
|
| Azathioprine | 1 | 2011 | 73 | 0.390 |
Why?
|
| Clinical Trials as Topic | 9 | 2023 | 3844 | 0.390 |
Why?
|
| Lymph Nodes | 10 | 2021 | 3077 | 0.390 |
Why?
|
| Prostate | 4 | 2013 | 1089 | 0.390 |
Why?
|
| Kidney Neoplasms | 4 | 2022 | 3108 | 0.390 |
Why?
|
| Biomarkers, Tumor | 17 | 2021 | 10708 | 0.390 |
Why?
|
| Immunity, Cellular | 6 | 2015 | 440 | 0.380 |
Why?
|
| Mercaptopurine | 1 | 2011 | 130 | 0.380 |
Why?
|
| Colonoscopy | 6 | 2023 | 522 | 0.370 |
Why?
|
| Female | 79 | 2024 | 148940 | 0.370 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2022 | 2386 | 0.370 |
Why?
|
| Drug Delivery Systems | 1 | 2015 | 661 | 0.370 |
Why?
|
| Th1 Cells | 2 | 2021 | 259 | 0.360 |
Why?
|
| Toll-Like Receptors | 1 | 2011 | 170 | 0.360 |
Why?
|
| Receptors, IgG | 4 | 2024 | 116 | 0.360 |
Why?
|
| Aged | 51 | 2024 | 73333 | 0.360 |
Why?
|
| Middle Aged | 58 | 2024 | 90352 | 0.360 |
Why?
|
| Autoimmune Diseases | 4 | 2009 | 436 | 0.350 |
Why?
|
| Gene Deletion | 1 | 2015 | 1474 | 0.350 |
Why?
|
| Cytokines | 13 | 2019 | 2825 | 0.350 |
Why?
|
| Immunomodulation | 4 | 2017 | 255 | 0.340 |
Why?
|
| Leukemia, T-Cell | 1 | 2010 | 90 | 0.340 |
Why?
|
| Membrane Proteins | 10 | 2021 | 2928 | 0.340 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 4 | 1995 | 41 | 0.340 |
Why?
|
| Immunoglobulins | 2 | 2009 | 286 | 0.330 |
Why?
|
| Lung Neoplasms | 11 | 2023 | 12033 | 0.330 |
Why?
|
| Models, Immunological | 5 | 2012 | 79 | 0.330 |
Why?
|
| Apoptosis Regulatory Proteins | 4 | 2009 | 622 | 0.330 |
Why?
|
| Cytotoxicity, Immunologic | 6 | 2024 | 683 | 0.320 |
Why?
|
| Immunophenotyping | 7 | 2019 | 1726 | 0.320 |
Why?
|
| Colitis, Ulcerative | 2 | 2009 | 258 | 0.320 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2011 | 1584 | 0.320 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2023 | 5574 | 0.310 |
Why?
|
| Antigen Presentation | 6 | 2019 | 286 | 0.310 |
Why?
|
| Gastrointestinal Microbiome | 4 | 2021 | 980 | 0.310 |
Why?
|
| Tumor Escape | 5 | 2016 | 247 | 0.310 |
Why?
|
| Cryosurgery | 4 | 2021 | 196 | 0.310 |
Why?
|
| Biomedical Research | 1 | 2015 | 801 | 0.300 |
Why?
|
| Epitopes | 15 | 2014 | 707 | 0.300 |
Why?
|
| Periodicals as Topic | 1 | 2012 | 317 | 0.300 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 1563 | 0.300 |
Why?
|
| Urinary Bladder Neoplasms | 5 | 2020 | 2431 | 0.300 |
Why?
|
| HLA-A Antigens | 1 | 2008 | 105 | 0.290 |
Why?
|
| Interleukin-17 | 2 | 2024 | 255 | 0.290 |
Why?
|
| Bone Marrow Cells | 2 | 2018 | 968 | 0.290 |
Why?
|
| Cell Division | 4 | 2010 | 2657 | 0.280 |
Why?
|
| Neoadjuvant Therapy | 9 | 2023 | 5231 | 0.280 |
Why?
|
| Receptors, Complement | 1 | 2006 | 48 | 0.270 |
Why?
|
| Neoplasm Transplantation | 9 | 2015 | 1553 | 0.270 |
Why?
|
| Down-Regulation | 3 | 2006 | 2090 | 0.260 |
Why?
|
| Antigens, Ly | 2 | 2002 | 51 | 0.260 |
Why?
|
| Immunosuppressive Agents | 6 | 2015 | 1432 | 0.260 |
Why?
|
| Endothelium, Vascular | 1 | 2010 | 879 | 0.260 |
Why?
|
| Mass Screening | 4 | 2023 | 1552 | 0.260 |
Why?
|
| Carcinoma | 3 | 2020 | 2610 | 0.260 |
Why?
|
| Nematode Infections | 1 | 2005 | 8 | 0.260 |
Why?
|
| Amino Acid Sequence | 15 | 2012 | 4567 | 0.250 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2005 | 52 | 0.250 |
Why?
|
| Gene Library | 1 | 2006 | 353 | 0.250 |
Why?
|
| Antibodies | 9 | 2015 | 809 | 0.250 |
Why?
|
| Biomarkers | 9 | 2020 | 5051 | 0.250 |
Why?
|
| Forecasting | 2 | 2021 | 702 | 0.250 |
Why?
|
| Blood Proteins | 2 | 2003 | 299 | 0.250 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2021 | 7265 | 0.240 |
Why?
|
| Clonal Evolution | 2 | 2017 | 250 | 0.240 |
Why?
|
| Lectins, C-Type | 3 | 2013 | 163 | 0.240 |
Why?
|
| Adult | 38 | 2024 | 82040 | 0.240 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2024 | 26 | 0.240 |
Why?
|
| Neutrophils | 3 | 2021 | 873 | 0.230 |
Why?
|
| Transcription Factors | 4 | 2020 | 5438 | 0.230 |
Why?
|
| Interferon Type I | 2 | 2016 | 282 | 0.230 |
Why?
|
| Abiraterone Acetate | 1 | 2024 | 89 | 0.220 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2010 | 999 | 0.220 |
Why?
|
| Lymphocyte Depletion | 5 | 2013 | 316 | 0.220 |
Why?
|
| Cell Movement | 5 | 2021 | 2472 | 0.220 |
Why?
|
| Liver Neoplasms | 4 | 2022 | 4821 | 0.220 |
Why?
|
| Myositis | 1 | 2024 | 87 | 0.220 |
Why?
|
| Cell Proliferation | 10 | 2019 | 7238 | 0.220 |
Why?
|
| Single-Cell Analysis | 4 | 2024 | 557 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2020 | 10400 | 0.220 |
Why?
|
| Ventricular Myosins | 1 | 2022 | 7 | 0.220 |
Why?
|
| Interleukin-2 | 11 | 2012 | 889 | 0.210 |
Why?
|
| Pilot Projects | 8 | 2021 | 2828 | 0.210 |
Why?
|
| Recombination, Genetic | 4 | 2017 | 665 | 0.210 |
Why?
|
| Histamine H2 Antagonists | 1 | 2003 | 58 | 0.210 |
Why?
|
| Glioblastoma | 3 | 2020 | 1776 | 0.210 |
Why?
|
| Interleukin-6 | 3 | 2022 | 1050 | 0.210 |
Why?
|
| Peptide Fragments | 7 | 2011 | 1309 | 0.210 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 3 | 2015 | 105 | 0.210 |
Why?
|
| Anti-Ulcer Agents | 1 | 2003 | 127 | 0.210 |
Why?
|
| Ovalbumin | 2 | 2015 | 390 | 0.210 |
Why?
|
| Peptic Ulcer | 1 | 2003 | 161 | 0.200 |
Why?
|
| Cells, Cultured | 12 | 2021 | 5694 | 0.200 |
Why?
|
| Immunohistochemistry | 13 | 2019 | 7655 | 0.200 |
Why?
|
| Myeloid Cells | 3 | 2022 | 273 | 0.200 |
Why?
|
| Aged, 80 and over | 19 | 2024 | 30998 | 0.200 |
Why?
|
| History, 21st Century | 2 | 2015 | 419 | 0.200 |
Why?
|
| Lymphoma, T-Cell | 1 | 2005 | 366 | 0.190 |
Why?
|
| Fecal Microbiota Transplantation | 2 | 2021 | 168 | 0.190 |
Why?
|
| Phenotype | 7 | 2024 | 6509 | 0.190 |
Why?
|
| Pancreatic Neoplasms | 4 | 2024 | 5257 | 0.190 |
Why?
|
| Leukemic Infiltration | 2 | 2018 | 73 | 0.190 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 2 | 2019 | 19 | 0.190 |
Why?
|
| Receptors, Interleukin-2 | 5 | 2015 | 195 | 0.190 |
Why?
|
| Molecular Sequence Data | 11 | 2008 | 6685 | 0.190 |
Why?
|
| Prednisone | 1 | 2024 | 1034 | 0.190 |
Why?
|
| Dietary Fiber | 1 | 2021 | 127 | 0.190 |
Why?
|
| Graft vs Host Disease | 6 | 2019 | 2810 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 3 | 2020 | 2399 | 0.190 |
Why?
|
| Nucleocapsid | 1 | 2020 | 13 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 1412 | 0.180 |
Why?
|
| B7-2 Antigen | 5 | 2004 | 53 | 0.180 |
Why?
|
| Drug Discovery | 2 | 2021 | 329 | 0.180 |
Why?
|
| Anticholesteremic Agents | 1 | 2023 | 249 | 0.180 |
Why?
|
| Myelodysplastic Syndromes | 3 | 2019 | 3156 | 0.180 |
Why?
|
| Inducible T-Cell Co-Stimulator Ligand | 2 | 2017 | 22 | 0.180 |
Why?
|
| Fibrosarcoma | 3 | 2002 | 143 | 0.180 |
Why?
|
| Histones | 1 | 2008 | 1513 | 0.180 |
Why?
|
| Cell Communication | 4 | 2012 | 512 | 0.170 |
Why?
|
| Histocompatibility Antigens Class I | 5 | 2024 | 247 | 0.170 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2006 | 1710 | 0.170 |
Why?
|
| Up-Regulation | 6 | 2017 | 2422 | 0.170 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2020 | 37 | 0.170 |
Why?
|
| CD8 Antigens | 2 | 2006 | 174 | 0.170 |
Why?
|
| Autoimmune Hypophysitis | 1 | 2019 | 13 | 0.170 |
Why?
|
| Crohn Disease | 2 | 2016 | 328 | 0.170 |
Why?
|
| HLA Antigens | 8 | 1987 | 594 | 0.170 |
Why?
|
| 5'-Nucleotidase | 1 | 2019 | 63 | 0.170 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2023 | 481 | 0.170 |
Why?
|
| Neoplasm Staging | 11 | 2022 | 14012 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2024 | 9042 | 0.170 |
Why?
|
| Transforming Growth Factor beta | 3 | 2011 | 1109 | 0.160 |
Why?
|
| Mice, Inbred Strains | 6 | 2010 | 563 | 0.160 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2019 | 101 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2011 | 1525 | 0.160 |
Why?
|
| Cell Lineage | 2 | 2019 | 701 | 0.160 |
Why?
|
| Lipopeptides | 1 | 2019 | 117 | 0.160 |
Why?
|
| H-2 Antigens | 3 | 2002 | 43 | 0.160 |
Why?
|
| Epithelium | 6 | 1993 | 782 | 0.160 |
Why?
|
| Urothelium | 1 | 2020 | 264 | 0.160 |
Why?
|
| Probiotics | 1 | 2021 | 241 | 0.160 |
Why?
|
| Cloning, Molecular | 5 | 2008 | 1430 | 0.160 |
Why?
|
| Inflammation | 5 | 2022 | 2518 | 0.160 |
Why?
|
| Survival Analysis | 8 | 2020 | 9292 | 0.160 |
Why?
|
| Ovarian Neoplasms | 3 | 2010 | 4795 | 0.160 |
Why?
|
| Immunoassay | 2 | 2018 | 214 | 0.160 |
Why?
|
| Sarcoma | 3 | 2021 | 1839 | 0.160 |
Why?
|
| CD4 Antigens | 5 | 2013 | 170 | 0.160 |
Why?
|
| Thymoma | 2 | 1994 | 252 | 0.160 |
Why?
|
| Adjuvants, Immunologic | 3 | 2009 | 695 | 0.160 |
Why?
|
| Gene Expression | 4 | 2019 | 3640 | 0.150 |
Why?
|
| Immunity, Innate | 3 | 2011 | 699 | 0.150 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 212 | 0.150 |
Why?
|
| Immunity | 4 | 2019 | 354 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2012 | 451 | 0.150 |
Why?
|
| Autoantibodies | 2 | 2019 | 602 | 0.150 |
Why?
|
| United States | 8 | 2015 | 15861 | 0.150 |
Why?
|
| Healthcare Disparities | 2 | 2014 | 657 | 0.150 |
Why?
|
| Protein Binding | 3 | 2020 | 3485 | 0.150 |
Why?
|
| Dactinomycin | 1 | 2018 | 163 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2022 | 2175 | 0.150 |
Why?
|
| Brain Neoplasms | 4 | 2019 | 4958 | 0.150 |
Why?
|
| CD30 Ligand | 1 | 2017 | 13 | 0.150 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2017 | 19 | 0.150 |
Why?
|
| Sigmoidoscopy | 2 | 2014 | 49 | 0.150 |
Why?
|
| Immune Sera | 4 | 1984 | 145 | 0.150 |
Why?
|
| Synapses | 1 | 2002 | 546 | 0.150 |
Why?
|
| Clonal Deletion | 1 | 1997 | 7 | 0.140 |
Why?
|
| Survival Rate | 9 | 2022 | 12541 | 0.140 |
Why?
|
| Prognosis | 10 | 2020 | 22505 | 0.140 |
Why?
|
| Idarubicin | 1 | 2019 | 459 | 0.140 |
Why?
|
| Homeostasis | 1 | 2002 | 925 | 0.140 |
Why?
|
| Treatment Outcome | 18 | 2021 | 33737 | 0.140 |
Why?
|
| Genomics | 2 | 2020 | 2835 | 0.140 |
Why?
|
| Tissue Array Analysis | 3 | 2017 | 757 | 0.140 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2018 | 264 | 0.140 |
Why?
|
| Disease Progression | 5 | 2021 | 6867 | 0.140 |
Why?
|
| Spleen | 5 | 2015 | 726 | 0.140 |
Why?
|
| Receptors, Interferon | 1 | 2016 | 42 | 0.140 |
Why?
|
| Drug Therapy, Combination | 3 | 2022 | 2345 | 0.140 |
Why?
|
| Clone Cells | 5 | 2020 | 591 | 0.140 |
Why?
|
| Medically Uninsured | 2 | 2014 | 106 | 0.140 |
Why?
|
| Oximes | 1 | 2018 | 191 | 0.140 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 518 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2019 | 1828 | 0.130 |
Why?
|
| Cell Line | 12 | 2008 | 5338 | 0.130 |
Why?
|
| Hybridomas | 6 | 2008 | 70 | 0.130 |
Why?
|
| Interleukin-7 | 1 | 2016 | 92 | 0.130 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2017 | 191 | 0.130 |
Why?
|
| Lymphocytes | 7 | 2014 | 1275 | 0.130 |
Why?
|
| Adaptive Immunity | 2 | 2020 | 151 | 0.130 |
Why?
|
| Pyrimidinones | 1 | 2018 | 318 | 0.130 |
Why?
|
| Cricetinae | 2 | 2009 | 769 | 0.130 |
Why?
|
| Preoperative Care | 2 | 2019 | 1567 | 0.130 |
Why?
|
| Breast Neoplasms | 4 | 2016 | 16215 | 0.130 |
Why?
|
| Prescription Fees | 1 | 2015 | 17 | 0.130 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 824 | 0.130 |
Why?
|
| T-Cell Antigen Receptor Specificity | 3 | 2010 | 92 | 0.130 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 3 | 1990 | 67 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 514 | 0.130 |
Why?
|
| Mutation | 8 | 2020 | 15912 | 0.120 |
Why?
|
| Pancreas | 2 | 2024 | 744 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2018 | 625 | 0.120 |
Why?
|
| Pyridones | 1 | 2018 | 360 | 0.120 |
Why?
|
| Patient Advocacy | 1 | 2015 | 90 | 0.120 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2015 | 64 | 0.120 |
Why?
|
| Tumor Burden | 3 | 2017 | 2033 | 0.120 |
Why?
|
| Imatinib Mesylate | 2 | 2017 | 1691 | 0.120 |
Why?
|
| Vagina | 2 | 2015 | 331 | 0.120 |
Why?
|
| Tissue Donors | 1 | 2019 | 821 | 0.120 |
Why?
|
| Cohort Studies | 7 | 2021 | 9470 | 0.120 |
Why?
|
| Trypsin | 4 | 2010 | 156 | 0.120 |
Why?
|
| Melphalan | 1 | 2018 | 879 | 0.120 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 322 | 0.120 |
Why?
|
| Radioimmunotherapy | 1 | 2015 | 128 | 0.120 |
Why?
|
| CD3 Complex | 6 | 2005 | 320 | 0.120 |
Why?
|
| Bone Marrow Transplantation | 3 | 2019 | 1757 | 0.120 |
Why?
|
| DNA-Binding Proteins | 6 | 2020 | 5002 | 0.120 |
Why?
|
| Fibrosis | 2 | 2015 | 733 | 0.120 |
Why?
|
| Immunochemistry | 1 | 2014 | 61 | 0.120 |
Why?
|
| Phosphorylation | 4 | 2016 | 4942 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2017 | 3917 | 0.120 |
Why?
|
| Endometrial Neoplasms | 1 | 2023 | 1385 | 0.110 |
Why?
|
| Guaiac | 1 | 2013 | 6 | 0.110 |
Why?
|
| Drug Costs | 1 | 2015 | 140 | 0.110 |
Why?
|
| Leukocyte Common Antigens | 2 | 2010 | 191 | 0.110 |
Why?
|
| Insurance Coverage | 2 | 2014 | 275 | 0.110 |
Why?
|
| Gene Products, gag | 1 | 2013 | 35 | 0.110 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 1301 | 0.110 |
Why?
|
| Indicators and Reagents | 1 | 2013 | 137 | 0.110 |
Why?
|
| Infliximab | 2 | 2011 | 138 | 0.110 |
Why?
|
| Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 1993 | 3 | 0.110 |
Why?
|
| Endogenous Retroviruses | 1 | 2013 | 43 | 0.110 |
Why?
|
| Drug Approval | 1 | 2004 | 174 | 0.110 |
Why?
|
| Epidermis | 3 | 1989 | 196 | 0.110 |
Why?
|
| Major Histocompatibility Complex | 6 | 2006 | 99 | 0.110 |
Why?
|
| Helicobacter pylori | 1 | 2003 | 1436 | 0.110 |
Why?
|
| Helicobacter Infections | 1 | 2003 | 1353 | 0.110 |
Why?
|
| Pneumonia | 1 | 2019 | 796 | 0.110 |
Why?
|
| Medically Underserved Area | 1 | 2014 | 123 | 0.110 |
Why?
|
| Base Sequence | 8 | 2008 | 5437 | 0.110 |
Why?
|
| Salvage Therapy | 3 | 2018 | 2123 | 0.110 |
Why?
|
| Triazoles | 1 | 2017 | 627 | 0.110 |
Why?
|
| Cytarabine | 1 | 2019 | 2014 | 0.110 |
Why?
|
| Recombinant Proteins | 4 | 2015 | 3028 | 0.110 |
Why?
|
| Classification | 1 | 2012 | 39 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 625 | 0.100 |
Why?
|
| Anus Neoplasms | 1 | 2017 | 414 | 0.100 |
Why?
|
| Mice, Inbred CBA | 2 | 2006 | 79 | 0.100 |
Why?
|
| Papillomavirus Vaccines | 1 | 2015 | 197 | 0.100 |
Why?
|
| Interleukin-15 Receptor alpha Subunit | 1 | 2012 | 9 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 700 | 0.100 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2014 | 107 | 0.100 |
Why?
|
| In Vitro Techniques | 3 | 2017 | 1697 | 0.100 |
Why?
|
| Cell Count | 2 | 2010 | 512 | 0.100 |
Why?
|
| Single-Chain Antibodies | 1 | 2012 | 61 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2024 | 2453 | 0.100 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 1739 | 0.100 |
Why?
|
| Cell Membrane | 8 | 2013 | 878 | 0.100 |
Why?
|
| Sensitivity and Specificity | 3 | 2020 | 5162 | 0.100 |
Why?
|
| Immunity, Mucosal | 1 | 2002 | 121 | 0.100 |
Why?
|
| Academic Medical Centers | 3 | 2018 | 681 | 0.100 |
Why?
|
| Adalimumab | 1 | 2011 | 48 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2016 | 497 | 0.100 |
Why?
|
| Myelin-Associated Glycoprotein | 1 | 2011 | 18 | 0.100 |
Why?
|
| Cell Separation | 5 | 2015 | 609 | 0.100 |
Why?
|
| Imidazoles | 1 | 2018 | 1065 | 0.100 |
Why?
|
| Fibroblasts | 2 | 2017 | 1654 | 0.100 |
Why?
|
| Patient Preference | 1 | 2014 | 229 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 1347 | 0.100 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2011 | 42 | 0.100 |
Why?
|
| Internationality | 1 | 2012 | 205 | 0.100 |
Why?
|
| Advisory Committees | 1 | 2012 | 196 | 0.100 |
Why?
|
| Patient Participation | 1 | 2015 | 453 | 0.090 |
Why?
|
| Ki-67 Antigen | 2 | 2010 | 675 | 0.090 |
Why?
|
| Pandemics | 1 | 2020 | 1610 | 0.090 |
Why?
|
| Myelin Proteins | 1 | 2011 | 93 | 0.090 |
Why?
|
| Coculture Techniques | 2 | 2010 | 628 | 0.090 |
Why?
|
| ras Proteins | 1 | 2015 | 804 | 0.090 |
Why?
|
| Interleukin-15 | 1 | 2012 | 190 | 0.090 |
Why?
|
| Young Adult | 8 | 2021 | 22251 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 2486 | 0.090 |
Why?
|
| Colectomy | 2 | 2012 | 292 | 0.090 |
Why?
|
| Interinstitutional Relations | 2 | 2004 | 37 | 0.090 |
Why?
|
| Cytochromes c | 1 | 2010 | 117 | 0.090 |
Why?
|
| Graft Rejection | 2 | 1994 | 847 | 0.090 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2010 | 39 | 0.090 |
Why?
|
| Sirolimus | 1 | 2015 | 831 | 0.090 |
Why?
|
| HLA-DR Antigens | 1 | 2010 | 184 | 0.090 |
Why?
|
| Tissue Distribution | 2 | 2011 | 927 | 0.090 |
Why?
|
| Government Regulation | 2 | 2004 | 58 | 0.090 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2010 | 183 | 0.090 |
Why?
|
| Islets of Langerhans | 1 | 2011 | 236 | 0.090 |
Why?
|
| Drug Industry | 2 | 2004 | 88 | 0.090 |
Why?
|
| Mice, Inbred C3H | 5 | 1994 | 404 | 0.090 |
Why?
|
| Publishing | 1 | 2012 | 194 | 0.090 |
Why?
|
| Enzyme Inhibitors | 2 | 2018 | 1942 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 2224 | 0.090 |
Why?
|
| Carboxypeptidases A | 1 | 2009 | 7 | 0.090 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2012 | 217 | 0.090 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2004 | 197 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2014 | 2650 | 0.090 |
Why?
|
| Receptors, Virus | 2 | 2007 | 153 | 0.090 |
Why?
|
| Escherichia coli Proteins | 1 | 2002 | 377 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2010 | 207 | 0.080 |
Why?
|
| Resting Phase, Cell Cycle | 2 | 2006 | 38 | 0.080 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 1002 | 0.080 |
Why?
|
| Disulfides | 3 | 1985 | 111 | 0.080 |
Why?
|
| HLA-A2 Antigen | 2 | 2008 | 172 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 4 | 2015 | 3476 | 0.080 |
Why?
|
| Antigen-Antibody Reactions | 4 | 2006 | 89 | 0.080 |
Why?
|
| beta-N-Acetylhexosaminidases | 2 | 2007 | 28 | 0.080 |
Why?
|
| Solubility | 2 | 2008 | 247 | 0.080 |
Why?
|
| Macromolecular Substances | 5 | 1989 | 340 | 0.080 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 3339 | 0.080 |
Why?
|
| Multigene Family | 1 | 1990 | 469 | 0.080 |
Why?
|
| Nerve Growth Factor | 2 | 2007 | 42 | 0.080 |
Why?
|
| Gene Products, env | 1 | 1989 | 36 | 0.080 |
Why?
|
| Heat-Shock Proteins | 1 | 1990 | 327 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 3 | 2010 | 1189 | 0.080 |
Why?
|
| Th17 Cells | 1 | 2010 | 163 | 0.080 |
Why?
|
| United States Food and Drug Administration | 2 | 2004 | 323 | 0.080 |
Why?
|
| Lectins | 2 | 2007 | 148 | 0.080 |
Why?
|
| Self Tolerance | 1 | 2008 | 18 | 0.080 |
Why?
|
| Global Health | 1 | 2014 | 692 | 0.080 |
Why?
|
| Azacitidine | 3 | 2021 | 1218 | 0.080 |
Why?
|
| Medicare | 1 | 2014 | 926 | 0.080 |
Why?
|
| Drug Combinations | 2 | 2004 | 633 | 0.080 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2011 | 318 | 0.080 |
Why?
|
| Disease-Free Survival | 5 | 2019 | 10265 | 0.080 |
Why?
|
| Bone Neoplasms | 1 | 2021 | 2665 | 0.080 |
Why?
|
| Program Development | 1 | 2009 | 259 | 0.080 |
Why?
|
| Intestinal Mucosa | 3 | 2023 | 1105 | 0.080 |
Why?
|
| Immunologic Factors | 3 | 2022 | 672 | 0.080 |
Why?
|
| Proteins | 3 | 2007 | 2043 | 0.080 |
Why?
|
| Immunity, Active | 1 | 2007 | 14 | 0.080 |
Why?
|
| Receptors, Transferrin | 1 | 2007 | 41 | 0.080 |
Why?
|
| Feedback, Physiological | 1 | 2008 | 189 | 0.070 |
Why?
|
| Filariasis | 1 | 2007 | 31 | 0.070 |
Why?
|
| Incidence | 3 | 2014 | 5824 | 0.070 |
Why?
|
| RNA, Messenger | 4 | 2015 | 6390 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2019 | 1470 | 0.070 |
Why?
|
| Prostate-Specific Antigen | 2 | 2013 | 1029 | 0.070 |
Why?
|
| Mice, Nude | 4 | 2016 | 4329 | 0.070 |
Why?
|
| Interleukin-3 | 1 | 2007 | 106 | 0.070 |
Why?
|
| Genes | 2 | 1987 | 606 | 0.070 |
Why?
|
| Transcriptome | 3 | 2021 | 1963 | 0.070 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2005 | 550 | 0.070 |
Why?
|
| Vaccines | 1 | 2002 | 399 | 0.070 |
Why?
|
| Radiotherapy | 1 | 2014 | 1857 | 0.070 |
Why?
|
| Precision Medicine | 1 | 2015 | 1207 | 0.070 |
Why?
|
| Golgi Apparatus | 1 | 2007 | 151 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2015 | 2166 | 0.070 |
Why?
|
| Receptors, Complement 3b | 1 | 2006 | 20 | 0.070 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 1986 | 41 | 0.070 |
Why?
|
| Infant, Newborn | 2 | 2011 | 8699 | 0.070 |
Why?
|
| Kidney | 1 | 2015 | 2121 | 0.070 |
Why?
|
| Galectins | 1 | 2007 | 73 | 0.070 |
Why?
|
| Steroids | 1 | 2008 | 372 | 0.070 |
Why?
|
| Gene Expression Profiling | 4 | 2023 | 5149 | 0.070 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2006 | 175 | 0.070 |
Why?
|
| Exome | 1 | 2012 | 1248 | 0.070 |
Why?
|
| Ovary | 1 | 2010 | 688 | 0.070 |
Why?
|
| Binding, Competitive | 1 | 2006 | 329 | 0.070 |
Why?
|
| Molecular Weight | 8 | 2006 | 721 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2009 | 575 | 0.070 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1989 | 402 | 0.070 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 550 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2009 | 1356 | 0.070 |
Why?
|
| Ethionine | 1 | 1985 | 5 | 0.060 |
Why?
|
| Fetus | 4 | 1991 | 674 | 0.060 |
Why?
|
| Algorithms | 3 | 2019 | 3891 | 0.060 |
Why?
|
| 2-Acetylaminofluorene | 1 | 1985 | 14 | 0.060 |
Why?
|
| Choline Deficiency | 1 | 1985 | 10 | 0.060 |
Why?
|
| Vaccines, DNA | 3 | 2013 | 111 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 4147 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 5 | 2017 | 1121 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2007 | 659 | 0.060 |
Why?
|
| Insulin-Secreting Cells | 1 | 2007 | 160 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 3530 | 0.060 |
Why?
|
| Genes, Reporter | 1 | 2007 | 820 | 0.060 |
Why?
|
| Thy-1 Antigens | 4 | 1990 | 52 | 0.060 |
Why?
|
| Mice, Mutant Strains | 4 | 2007 | 655 | 0.060 |
Why?
|
| Bone Marrow | 4 | 2021 | 2441 | 0.060 |
Why?
|
| Genetic Therapy | 1 | 2012 | 1716 | 0.060 |
Why?
|
| Biopsy | 3 | 2017 | 3484 | 0.060 |
Why?
|
| Interleukin-4 | 1 | 2005 | 290 | 0.060 |
Why?
|
| DNA | 6 | 1991 | 3050 | 0.060 |
Why?
|
| Apoptosis | 2 | 2010 | 7757 | 0.060 |
Why?
|
| Androgens | 2 | 2004 | 506 | 0.060 |
Why?
|
| Adolescent | 5 | 2015 | 32767 | 0.060 |
Why?
|
| Thiohydantoins | 1 | 2024 | 28 | 0.060 |
Why?
|
| Hyperglycemia | 1 | 2007 | 337 | 0.060 |
Why?
|
| Genomic Instability | 1 | 2007 | 521 | 0.060 |
Why?
|
| Chemokine CCL5 | 1 | 2024 | 76 | 0.060 |
Why?
|
| Infant | 2 | 2011 | 13999 | 0.060 |
Why?
|
| Models, Biological | 2 | 2008 | 3194 | 0.060 |
Why?
|
| Lymphatic Metastasis | 3 | 2021 | 4963 | 0.060 |
Why?
|
| BCG Vaccine | 1 | 2007 | 428 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 5593 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 2 | 1984 | 809 | 0.060 |
Why?
|
| Thymus Neoplasms | 1 | 1989 | 416 | 0.060 |
Why?
|
| Italy | 1 | 2023 | 191 | 0.060 |
Why?
|
| Time Factors | 3 | 2021 | 13006 | 0.060 |
Why?
|
| Risk Factors | 3 | 2020 | 17888 | 0.060 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2003 | 21 | 0.060 |
Why?
|
| Rosuvastatin Calcium | 1 | 2023 | 49 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2011 | 17061 | 0.050 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2003 | 29 | 0.050 |
Why?
|
| Epithelial Cells | 3 | 2024 | 1875 | 0.050 |
Why?
|
| CHO Cells | 1 | 2003 | 320 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2009 | 831 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2016 | 1075 | 0.050 |
Why?
|
| Managed Care Programs | 1 | 2003 | 83 | 0.050 |
Why?
|
| Liver | 4 | 1985 | 3086 | 0.050 |
Why?
|
| Embryonic and Fetal Development | 2 | 1995 | 227 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2008 | 2057 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 2069 | 0.050 |
Why?
|
| STAT6 Transcription Factor | 1 | 2003 | 68 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2009 | 831 | 0.050 |
Why?
|
| Ezetimibe | 1 | 2023 | 97 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2019 | 7044 | 0.050 |
Why?
|
| Carrier Proteins | 3 | 2012 | 2098 | 0.050 |
Why?
|
| Receptors, NK Cell Lectin-Like | 1 | 2002 | 2 | 0.050 |
Why?
|
| Histocompatibility Antigen H-2D | 1 | 2002 | 6 | 0.050 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily A | 1 | 2002 | 4 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2018 | 749 | 0.050 |
Why?
|
| Piperazines | 1 | 2011 | 2145 | 0.050 |
Why?
|
| Mutation, Missense | 1 | 2008 | 1192 | 0.050 |
Why?
|
| Myelin Proteolipid Protein | 1 | 2002 | 29 | 0.050 |
Why?
|
| Evolution, Molecular | 1 | 2006 | 867 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2005 | 393 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2021 | 46 | 0.050 |
Why?
|
| DNA Methylation | 3 | 2018 | 2765 | 0.050 |
Why?
|
| Mice, Inbred DBA | 3 | 2005 | 117 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2007 | 841 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 768 | 0.050 |
Why?
|
| Aspartate Aminotransferases | 1 | 2022 | 147 | 0.050 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2002 | 219 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2024 | 483 | 0.050 |
Why?
|
| DNA Copy Number Variations | 2 | 2020 | 1568 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2024 | 420 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2023 | 311 | 0.050 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2002 | 381 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 1129 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2022 | 239 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 984 | 0.050 |
Why?
|
| Seroconversion | 1 | 2020 | 18 | 0.050 |
Why?
|
| Carboplatin | 1 | 2024 | 880 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2021 | 234 | 0.050 |
Why?
|
| Chemokine CXCL13 | 1 | 2020 | 20 | 0.040 |
Why?
|
| Biological Transport | 1 | 2002 | 626 | 0.040 |
Why?
|
| Taxoids | 1 | 2024 | 1015 | 0.040 |
Why?
|
| Neutrophil Activation | 1 | 2020 | 35 | 0.040 |
Why?
|
| California | 2 | 2012 | 212 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 1312 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2020 | 147 | 0.040 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2020 | 40 | 0.040 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2019 | 35 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2021 | 294 | 0.040 |
Why?
|
| Anilides | 1 | 2022 | 295 | 0.040 |
Why?
|
| Cardiotoxicity | 1 | 2020 | 152 | 0.040 |
Why?
|
| Immunosorbent Techniques | 2 | 1982 | 55 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2023 | 13414 | 0.040 |
Why?
|
| Glycoproteins | 4 | 1984 | 779 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2007 | 848 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2019 | 232 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 200 | 0.040 |
Why?
|
| Hospitalization | 1 | 2008 | 2167 | 0.040 |
Why?
|
| Mice, Inbred AKR | 2 | 1989 | 54 | 0.040 |
Why?
|
| Vaccination | 2 | 2003 | 1166 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2011 | 3669 | 0.040 |
Why?
|
| Genes, cdc | 1 | 2018 | 84 | 0.040 |
Why?
|
| Child | 2 | 2011 | 30559 | 0.040 |
Why?
|
| Isoantigens | 1 | 1978 | 66 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 5 | 1985 | 603 | 0.040 |
Why?
|
| Blotting, Southern | 2 | 1989 | 453 | 0.040 |
Why?
|
| San Francisco | 1 | 2018 | 24 | 0.040 |
Why?
|
| Lung | 2 | 2020 | 3298 | 0.040 |
Why?
|
| Spinal Cord | 1 | 2002 | 718 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2019 | 418 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2018 | 6224 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2024 | 1033 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2003 | 699 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2018 | 223 | 0.040 |
Why?
|
| Perioperative Care | 1 | 2022 | 447 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2007 | 1060 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 341 | 0.040 |
Why?
|
| Rabbits | 5 | 1990 | 1028 | 0.040 |
Why?
|
| DNA, Neoplasm | 2 | 2016 | 1958 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2021 | 550 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2019 | 561 | 0.040 |
Why?
|
| Spatial Analysis | 1 | 2017 | 32 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 722 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2016 | 2353 | 0.040 |
Why?
|
| Exanthema | 1 | 2019 | 212 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 1286 | 0.040 |
Why?
|
| Chromosome Deletion | 1 | 2021 | 1049 | 0.030 |
Why?
|
| Rats | 8 | 2012 | 6441 | 0.030 |
Why?
|
| Mohs Surgery | 1 | 2018 | 103 | 0.030 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 4372 | 0.030 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 1 | 2016 | 41 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2003 | 1624 | 0.030 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2016 | 49 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2019 | 324 | 0.030 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 164 | 0.030 |
Why?
|
| Antigens | 2 | 2009 | 281 | 0.030 |
Why?
|
| Spectrum Analysis | 1 | 2017 | 143 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2017 | 187 | 0.030 |
Why?
|
| Patient Safety | 1 | 2021 | 613 | 0.030 |
Why?
|
| Glycosylation | 1 | 2016 | 230 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2016 | 157 | 0.030 |
Why?
|
| Interferons | 1 | 2017 | 299 | 0.030 |
Why?
|
| Leukemia, Experimental | 2 | 1987 | 81 | 0.030 |
Why?
|
| Standard of Care | 1 | 2018 | 277 | 0.030 |
Why?
|
| Exercise | 1 | 2023 | 1184 | 0.030 |
Why?
|
| Organic Anion Transport Protein 1 | 1 | 2015 | 4 | 0.030 |
Why?
|
| Glioma | 1 | 2007 | 1978 | 0.030 |
Why?
|
| Aquaporin 1 | 1 | 2015 | 8 | 0.030 |
Why?
|
| fas Receptor | 1 | 1997 | 197 | 0.030 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2015 | 64 | 0.030 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2018 | 586 | 0.030 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 1995 | 56 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2017 | 338 | 0.030 |
Why?
|
| Organ Specificity | 2 | 2004 | 737 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 4960 | 0.030 |
Why?
|
| Cyclosporine | 2 | 1993 | 292 | 0.030 |
Why?
|
| Protein Stability | 1 | 2016 | 377 | 0.030 |
Why?
|
| Mast-Cell Sarcoma | 1 | 1994 | 5 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 6256 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 5056 | 0.030 |
Why?
|
| Disease Management | 1 | 2020 | 1090 | 0.030 |
Why?
|
| G2 Phase | 1 | 2015 | 218 | 0.030 |
Why?
|
| Cysteine | 2 | 2007 | 214 | 0.030 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2015 | 148 | 0.030 |
Why?
|
| Pyridines | 1 | 2022 | 1313 | 0.030 |
Why?
|
| Vaccines, Subunit | 1 | 2015 | 128 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2020 | 1154 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 2016 | 439 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2022 | 1269 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1995 | 471 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 15218 | 0.030 |
Why?
|
| Actins | 1 | 2017 | 602 | 0.030 |
Why?
|
| Immunization | 2 | 1986 | 399 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 2002 | 1435 | 0.030 |
Why?
|
| Macrophage-1 Antigen | 1 | 1993 | 55 | 0.030 |
Why?
|
| Viral Envelope Proteins | 2 | 1986 | 219 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2017 | 823 | 0.030 |
Why?
|
| Methylcholanthrene | 2 | 2012 | 32 | 0.030 |
Why?
|
| Protein Conformation | 2 | 2007 | 1254 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2015 | 295 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2016 | 579 | 0.030 |
Why?
|
| Erythrocyte Membrane | 2 | 1984 | 38 | 0.030 |
Why?
|
| Perforin | 1 | 2013 | 52 | 0.030 |
Why?
|
| Phagocytes | 1 | 2013 | 47 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 1076 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2016 | 690 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 1993 | 138 | 0.030 |
Why?
|
| Survival | 1 | 2013 | 183 | 0.030 |
Why?
|
| CD11b Antigen | 1 | 2013 | 64 | 0.030 |
Why?
|
| Vaccines, Synthetic | 1 | 2014 | 372 | 0.030 |
Why?
|
| Cisplatin | 1 | 2020 | 2497 | 0.030 |
Why?
|
| Genome | 1 | 2017 | 690 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2013 | 183 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2016 | 622 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 907 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2013 | 175 | 0.030 |
Why?
|
| Fas Ligand Protein | 1 | 2013 | 153 | 0.030 |
Why?
|
| Indoles | 1 | 2018 | 1028 | 0.030 |
Why?
|
| Disease Resistance | 1 | 2012 | 25 | 0.030 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2013 | 146 | 0.030 |
Why?
|
| Allografts | 1 | 2015 | 686 | 0.030 |
Why?
|
| Discrimination Learning | 1 | 1972 | 33 | 0.030 |
Why?
|
| Cholera Toxin | 1 | 2002 | 68 | 0.030 |
Why?
|
| Liver Neoplasms, Experimental | 3 | 1984 | 191 | 0.030 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 210 | 0.030 |
Why?
|
| Registries | 2 | 2012 | 2211 | 0.030 |
Why?
|
| Piperidines | 1 | 2018 | 1100 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 2067 | 0.030 |
Why?
|
| Nylons | 1 | 1972 | 20 | 0.030 |
Why?
|
| Orientation | 1 | 1972 | 55 | 0.030 |
Why?
|
| Enterotoxins | 1 | 2002 | 122 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 402 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2012 | 86 | 0.030 |
Why?
|
| Ganciclovir | 1 | 2012 | 194 | 0.030 |
Why?
|
| Interleukin-5 | 1 | 2012 | 69 | 0.030 |
Why?
|
| Leukemia, Lymphoid | 3 | 2006 | 289 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2017 | 1003 | 0.020 |
Why?
|
| Papillomaviridae | 1 | 2015 | 636 | 0.020 |
Why?
|
| Thymidine Kinase | 1 | 2012 | 223 | 0.020 |
Why?
|
| Emigrants and Immigrants | 1 | 2014 | 159 | 0.020 |
Why?
|
| Protein Engineering | 1 | 2012 | 100 | 0.020 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2012 | 115 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2002 | 290 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 7895 | 0.020 |
Why?
|
| Transplantation, Homologous | 2 | 2017 | 3046 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2018 | 6764 | 0.020 |
Why?
|
| Virion | 1 | 2002 | 186 | 0.020 |
Why?
|
| Minority Groups | 1 | 2014 | 328 | 0.020 |
Why?
|
| CD40 Antigens | 1 | 2012 | 106 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2003 | 3345 | 0.020 |
Why?
|
| Visual Perception | 1 | 1972 | 149 | 0.020 |
Why?
|
| Quinazolines | 1 | 2016 | 956 | 0.020 |
Why?
|
| Antibody Specificity | 2 | 1985 | 336 | 0.020 |
Why?
|
| Asparaginase | 1 | 1972 | 196 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2007 | 1824 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2012 | 323 | 0.020 |
Why?
|
| Bacterial Toxins | 1 | 2002 | 229 | 0.020 |
Why?
|
| Erythrocytes | 2 | 1982 | 337 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2020 | 2375 | 0.020 |
Why?
|
| Medicaid | 1 | 2014 | 306 | 0.020 |
Why?
|
| Pyrimidine Dimers | 1 | 1990 | 23 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 336 | 0.020 |
Why?
|
| Genes, Viral | 2 | 1989 | 257 | 0.020 |
Why?
|
| Chemistry | 2 | 1985 | 85 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 719 | 0.020 |
Why?
|
| Chemical Phenomena | 2 | 1985 | 120 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 2 | 1991 | 1367 | 0.020 |
Why?
|
| Urogenital Surgical Procedures | 1 | 2010 | 15 | 0.020 |
Why?
|
| Compassionate Use Trials | 1 | 2010 | 16 | 0.020 |
Why?
|
| International Cooperation | 1 | 2011 | 325 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1990 | 417 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2011 | 396 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 4 | 2005 | 85 | 0.020 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2012 | 256 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2011 | 507 | 0.020 |
Why?
|
| Recurrence | 1 | 2018 | 4878 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2013 | 1685 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2019 | 1383 | 0.020 |
Why?
|
| Chickens | 4 | 1984 | 783 | 0.020 |
Why?
|
| Mastectomy | 1 | 2016 | 1553 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 4000 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1997 | 1838 | 0.020 |
Why?
|
| Breast | 1 | 2016 | 1369 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 4048 | 0.020 |
Why?
|
| Chromosome Mapping | 2 | 1991 | 1655 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2014 | 618 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2011 | 659 | 0.020 |
Why?
|
| Intestine, Small | 1 | 1993 | 522 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2011 | 484 | 0.020 |
Why?
|
| Mice, SCID | 1 | 1993 | 1826 | 0.020 |
Why?
|
| Consensus | 1 | 2014 | 1106 | 0.020 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1989 | 93 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2012 | 494 | 0.020 |
Why?
|
| Viral Structural Proteins | 1 | 1989 | 61 | 0.020 |
Why?
|
| Peptide Mapping | 1 | 1989 | 118 | 0.020 |
Why?
|
| Retreatment | 1 | 2010 | 448 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2009 | 218 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 2573 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2015 | 1149 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 5759 | 0.020 |
Why?
|
| X-Rays | 1 | 1989 | 151 | 0.020 |
Why?
|
| International Classification of Diseases | 1 | 2009 | 98 | 0.020 |
Why?
|
| Rats, Inbred Strains | 2 | 1985 | 455 | 0.020 |
Why?
|
| Genes, MHC Class II | 2 | 1978 | 71 | 0.020 |
Why?
|
| Quality of Life | 1 | 2022 | 4761 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 1990 | 588 | 0.020 |
Why?
|
| DNA Replication | 1 | 1992 | 770 | 0.020 |
Why?
|
| Oncogenes | 1 | 2011 | 699 | 0.020 |
Why?
|
| Immunodominant Epitopes | 1 | 2008 | 63 | 0.020 |
Why?
|
| Erythrocyte Aging | 2 | 1984 | 11 | 0.020 |
Why?
|
| Social Class | 1 | 2009 | 324 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 1125 | 0.020 |
Why?
|
| Liver Regeneration | 2 | 1985 | 133 | 0.020 |
Why?
|
| Immunologic Techniques | 4 | 1984 | 44 | 0.020 |
Why?
|
| Leukemia Virus, Murine | 1 | 1987 | 20 | 0.020 |
Why?
|
| Brugia malayi | 1 | 2007 | 43 | 0.020 |
Why?
|
| Arginase | 1 | 2007 | 42 | 0.020 |
Why?
|
| Species Specificity | 2 | 2006 | 794 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 886 | 0.020 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2009 | 165 | 0.020 |
Why?
|
| Macrophage Activation | 1 | 2007 | 151 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 2359 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 1903 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2012 | 1497 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2012 | 1857 | 0.020 |
Why?
|
| Retroviridae Proteins | 1 | 1986 | 24 | 0.020 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2009 | 275 | 0.020 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1987 | 73 | 0.020 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2007 | 59 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 2184 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 6449 | 0.020 |
Why?
|
| Pregnancy | 2 | 1993 | 8130 | 0.020 |
Why?
|
| Kinetics | 2 | 1984 | 2220 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2016 | 2651 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 3216 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2007 | 105 | 0.020 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2005 | 15 | 0.020 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2005 | 19 | 0.020 |
Why?
|
| Cross Reactions | 2 | 1984 | 263 | 0.020 |
Why?
|
| Benzamides | 1 | 2011 | 1879 | 0.020 |
Why?
|
| Gene Amplification | 1 | 1988 | 766 | 0.020 |
Why?
|
| gamma-Glutamyltransferase | 1 | 1985 | 55 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 1990 | 1368 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2007 | 354 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2012 | 1563 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2009 | 565 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 3584 | 0.020 |
Why?
|
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 1985 | 23 | 0.020 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2005 | 16 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2007 | 384 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2007 | 634 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2012 | 1253 | 0.020 |
Why?
|
| Complement System Proteins | 2 | 1984 | 135 | 0.020 |
Why?
|
| Cobalt Radioisotopes | 1 | 2005 | 41 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 3597 | 0.020 |
Why?
|
| Sulfur Radioisotopes | 1 | 1984 | 29 | 0.020 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2005 | 56 | 0.020 |
Why?
|
| Point Mutation | 1 | 2008 | 788 | 0.020 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2005 | 52 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 1987 | 1028 | 0.020 |
Why?
|
| Extracellular Matrix | 2 | 1985 | 524 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2007 | 896 | 0.020 |
Why?
|
| Sexual Maturation | 1 | 2004 | 55 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2005 | 581 | 0.010 |
Why?
|
| Gestational Age | 1 | 1988 | 1173 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 2005 | 167 | 0.010 |
Why?
|
| Rosette Formation | 1 | 1984 | 38 | 0.010 |
Why?
|
| Orchiectomy | 1 | 2004 | 211 | 0.010 |
Why?
|
| alpha-Fetoproteins | 1 | 1985 | 255 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 1985 | 275 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1985 | 230 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 2004 | 115 | 0.010 |
Why?
|
| Hematopoiesis | 1 | 2007 | 602 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2003 | 13 | 0.010 |
Why?
|
| Vitiligo | 1 | 2003 | 17 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2007 | 1472 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1993 | 248 | 0.010 |
Why?
|
| Brain | 1 | 2017 | 4208 | 0.010 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2003 | 94 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2003 | 58 | 0.010 |
Why?
|
| Health Status | 1 | 2007 | 631 | 0.010 |
Why?
|
| Bile | 1 | 1983 | 85 | 0.010 |
Why?
|
| Retroviridae | 1 | 1984 | 373 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2003 | 65 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 7783 | 0.010 |
Why?
|
| Avian Leukosis | 1 | 1982 | 1 | 0.010 |
Why?
|
| Dermatitis | 1 | 2003 | 61 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 342 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 5101 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2003 | 190 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2004 | 294 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2003 | 591 | 0.010 |
Why?
|
| Alleles | 1 | 1988 | 2600 | 0.010 |
Why?
|
| Butanols | 1 | 1981 | 5 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1984 | 520 | 0.010 |
Why?
|
| Plasmids | 1 | 2004 | 936 | 0.010 |
Why?
|
| Microdissection | 1 | 2001 | 85 | 0.010 |
Why?
|
| Castration | 1 | 2001 | 122 | 0.010 |
Why?
|
| Sarcoma, Experimental | 1 | 1981 | 68 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 6177 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 2001 | 252 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2018 | 39890 | 0.010 |
Why?
|
| Necrosis | 1 | 2003 | 595 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2007 | 2580 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 3 | 1987 | 122 | 0.010 |
Why?
|
| Isoantibodies | 2 | 1978 | 120 | 0.010 |
Why?
|
| Transgenes | 1 | 2001 | 576 | 0.010 |
Why?
|
| Lipoproteins, HDL | 2 | 1977 | 127 | 0.010 |
Why?
|
| Sialoglycoproteins | 1 | 1979 | 151 | 0.010 |
Why?
|
| Fetal Blood | 1 | 1982 | 501 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 4492 | 0.010 |
Why?
|
| Antibody Formation | 2 | 1977 | 386 | 0.010 |
Why?
|
| Hot Temperature | 2 | 1985 | 289 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2013 | 5681 | 0.010 |
Why?
|
| Immunosorbents | 1 | 1977 | 10 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 1978 | 189 | 0.010 |
Why?
|
| Chemical Precipitation | 1 | 1977 | 27 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2003 | 1281 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2005 | 4019 | 0.010 |
Why?
|
| Endotoxins | 1 | 1975 | 96 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1977 | 1054 | 0.010 |
Why?
|
| Neuraminidase | 2 | 1984 | 46 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 3438 | 0.010 |
Why?
|
| Clonal Anergy | 1 | 1993 | 12 | 0.010 |
Why?
|
| Ionomycin | 1 | 1993 | 35 | 0.010 |
Why?
|
| CD2 Antigens | 1 | 1993 | 30 | 0.010 |
Why?
|
| Housing, Animal | 1 | 1972 | 41 | 0.010 |
Why?
|
| Methods | 1 | 1972 | 223 | 0.010 |
Why?
|
| Aldehydes | 1 | 1972 | 46 | 0.010 |
Why?
|
| Drug Stability | 1 | 1972 | 106 | 0.010 |
Why?
|
| Asparagine | 1 | 1972 | 44 | 0.010 |
Why?
|
| Task Performance and Analysis | 1 | 1972 | 121 | 0.010 |
Why?
|
| Aspartic Acid | 1 | 1972 | 136 | 0.010 |
Why?
|
| Chromatography, Affinity | 2 | 1983 | 144 | 0.010 |
Why?
|
| Light | 1 | 1972 | 279 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1972 | 600 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1990 | 350 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1991 | 356 | 0.010 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1989 | 36 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1989 | 330 | 0.000 |
Why?
|
| Concanavalin A | 1 | 1987 | 63 | 0.000 |
Why?
|
| Radiation Tolerance | 1 | 1991 | 639 | 0.000 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1989 | 257 | 0.000 |
Why?
|
| Isoflurophate | 1 | 1985 | 2 | 0.000 |
Why?
|
| Mercaptoethanol | 1 | 1985 | 16 | 0.000 |
Why?
|
| Staphylococcal Protein A | 1 | 1982 | 16 | 0.000 |
Why?
|
| Alpharetrovirus | 1 | 1982 | 7 | 0.000 |
Why?
|
| Hemagglutination Tests | 1 | 1982 | 28 | 0.000 |
Why?
|
| DNA Damage | 1 | 1990 | 1989 | 0.000 |
Why?
|
| Chick Embryo | 1 | 1982 | 220 | 0.000 |
Why?
|
| Hemolysis | 1 | 1982 | 126 | 0.000 |
Why?
|
| Birds | 1 | 1982 | 98 | 0.000 |
Why?
|
| Plasmacytoma | 1 | 1982 | 125 | 0.000 |
Why?
|
| Embryo, Mammalian | 1 | 1984 | 746 | 0.000 |
Why?
|
| Goats | 1 | 1977 | 69 | 0.000 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1976 | 102 | 0.000 |
Why?
|
| Mice, Inbred NZB | 1 | 1975 | 5 | 0.000 |
Why?
|
| Urine | 1 | 1976 | 135 | 0.000 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1975 | 159 | 0.000 |
Why?
|
| Blood Chemical Analysis | 1 | 1976 | 113 | 0.000 |
Why?
|
| Iodoacetamide | 1 | 1975 | 4 | 0.000 |
Why?
|
| Aging | 1 | 1982 | 1534 | 0.000 |
Why?
|